田红旗  性别：男。天津科技大学教授，2009年至今被天津国际生物医药联合研究院聘为学术带头人(PI)。学科方向：药物化学 招生方向：药物化学。1990年7月本科毕业于四川大学化学系，1998年获中科院上海有机化学研究所博士。2010年6月至今，南开大学药学院教授，博士生导师；2001年6月至今，阿瑞制药公司， 高级研究科学家（Senior Research Scientist）；1998年9月至2001年5月，科罗拉多大学化学系博士后；1990年7月至1993年8月,原化学工业部感光化学研究院助理工程师。
通过结构-活性关系（SAR）的研究对先导化合物进行最佳优化来开发新药；对受体蛋白激酶领域的靶标受体有一定程度的了解，并据此提出治疗癌症的新药开发的项目；具有开发新有机反应方法学研究的特长；具有对有机化合物进行工业化工艺研究的特长；熟悉通过各种分析仪器（如核磁共振、液-质联用仪、液相色谱、气相色谱、红外和质谱仪等）对有机化合物进行结构确定，及其他各种所需要的特征化。1. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. T. Richardson; S. Frank; M. Wang; C. Clarke; S. Jones; B. Ying; D. Kohlman; O. Wallace; T. Shepherd; R. Dally; A. Palkowitz; A. Geiser; H. Bryant; J. Henck; I. Cohen; D. Rudmann; D. McCann; D. Coutant; S. Oldham; C. Hummel; K. Fong; R. Hinklin; G. Lewis; H. Tian; J. Dodge. Bioorganic & Medicinal Chemistry Letters, 2007, 17(13), 3544-3549.2. A Selective Estrogen Receptor Modulator Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats. C. Hummel; A. Geiser; H. Bryant; I. Cohen; R. Dally; K. Fong; S. Frank; R. Hinklin; S. Jones; G. Lewis; D. McCann; D. Rudmann; T. Shepherd; H. Tian; O. Wallace; M. Wang; Y. Wang; J. Dodge. Journal of Medicinal Chemistry, 2005, 48(22), 6772-6775.3. Asymmetric Strecker Reaction of g-Keto Acids. Facile Entry to a-Substituted and a,g-Disubstituted Glutamic Acids. G. Tang, H. Tian, D. Ma*, Tetrahedron, 2004, 60(46), 10547-10552.4. Asymmetric Synthesis of (S)-1-Aminoindan-1,5-dicarboxylic Acid and Related Analogues via Intramolecular Acylation of Enantiopure α,α-Disubtituted Amino Acids. D. Ma*, D. Ke, H. Tian, B. Wang, D. Cheng, Tetrahedron: Asymmetry, 2002, 13(9), 961-969.5. Designing New Chiral Ketone Catalysts. Enantioselective Epoxidation of cis- and Terminal Olefins, H. Tian, X. She, H. Yu, L. Shu, Y. Shi*, J. Org. Chem., 2002, 67(8), 2435-2446.6. Enantioselective Epoxidation of Terminal Olefins by Chiral Dioxriane, H. Tian, X. She, J. Xu, Y. Shi*, Org. Lett., 2001, 3(12), 1929-1931.7. Electronic Probing of Ketone Catalysts for Asymmetric Epoxidation. Search for More Robust Catalyst, H. Tian, X. She, Y. Shi*, Org. Lett., 2001, 3(5), 715-718.8. Highly Enantioselective Epoxidation of cis-Olefins by Chiral Dioxirane, H. Tian, X. She, L. Shu, H. Yu, Y. Shi*, J. Am. Chem. Soc., 2000, 122, 11551-11552.9. Oxidation of Benzylic Methylene Compounds to Ketones with m- Chloroperoxybenzoic Acid and Oxygen, D. Ma*, C. Xia, H. Tian, Tetrahedron Lett. 1999, 40(50), 8915-8917.10. Enantioselective Syntheses of a-Substituted Glutamic Acids and a, g- Disubstituted Glutamic Acids by an Asymmetric Strecker Reaction, D. Ma*, G. Tang, H. Tian, G. Zou, Tetrahedron Lett. 1999, 40(31), 5753-5756.11. Asymmetric Strecker-Type Reaction of a-Aryl Ketones. Synthesis of s-aM4CPG, s-MPPG, s-AIDA, and s-APICA, the Antagonists of Metabotropic Glutamate Receptors, D. Ma*, H. Tian, G. Zou, J. Org. Chem., 1999, 64(1), 120-125.12. Stereoselective Synthesis of s-MPPG, s-MTPG, and s-(+)-aM4CPG from R-4-Hydroxyphenylglycine, D. Ma*, H. Tian, J. Chem. Soc. Perkin. Transactions I, 1997, 23, 3493-3496.13. Synthesis and Biological Activity of Cyclic Analogues of MPPG and MCPG as Metabotropic Receptor Antagonists, D. Ma*, H. Tian, H. Sun, A. P. Kozikowski, S. Pshenichkin, J. T. Wroblewsk, Biorg. & Med. Chem. Lett., 1997, 7(9), 1195-1198.14. Asymmetric Synthesis of (+)-4CPMG, a Selective Antagonist of Metabotropic Glutamate Receptors, D. Ma*, H. Tian. Tetrahedron: Asymmetry, 1996, 7(6), 1567-1570.发表的专利1. Preparation of pyrrolidinone and piperidinone derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace.2. Preparation of pyrrolidones and piperidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace; A. Krasutsky; J. Allen.3. Preparation of cycloalkyl lactam derivatives, particularly N-substituted pyrrolidin-2-ones, as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace; Z. Chen; T. Mabry; J. Mccowan; N. Snyder; L. Winneroski; J. Allen.4. Heterobicyclic thiophene compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; J. DeMeese; J. Gaudino; A. Marlow; J. Seo; A. Thomas; H. Tian. US 2007197537.5. Heterobicyclic pyrazole compounds as Met tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; F. Cohen; J DeMeese; K. Fong; J. Gaudino; T. Kaplan; A. Marlow; J. Seo; A. Thomas; H. Tian; W. Young.6. Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; P. Anzeveno; A. Krasutsky; R. Li; T. Mabry; A. Saeed; N. Snyder; G. Stephenson; H. Tian; O. Wallace; L. Winneroski; Y. Xu. (Note: this patent had been applied to additional 16 countries besides of the counties designated in WO).7. Preparation of quinoline derivatives as tyrosine kinases inhibitors. J. Gaudino; S. Boyd; A. Marlow; T. Kaplan; K. Fong; J. Seo; H. Tian; J. Blake; K. Koch.8. Heterobicyclic Pyrazolopyridine Compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; F. Cohen; J DeMeese; K. Fong; J. Gaudino; A. Marlow; J. Seo; A. Thomas; H. Tian; W. Young. Had been applied.9. Heterobicyclic Azaindole Compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; K. Fong; J. Gaudino; H. Tian. Manuscript in preparation.
兼职  